Year: 2021
Type: review
Abstract: Vesicular glutamate transporters (VGLUTs) were long thought to be specific markers of glutamatergic excitatory transmission. The discovery, two decades ago, of the atypical VGLUT3 has thoroughly modified this oversimplified view. VGLUT3 is strategically expressed in discrete populations of glutamatergic, cholinergic, serotonergic, and even GABAergic neurons. Recent reports show the subtle, but critical, implications of VGLUT3-dependent glutamate co-transmission and its roles in the regulation of diverse brain functions and dysfunctions. Progress in the neuropharmacology of VGLUT3 could lead to decisive breakthroughs in the treatment of Parkinson's disease (PD), addiction, eating disorders, anxiety, presbycusis, or pain. This review summarizes recent findings on VGLUT3 and its vesicular underpinnings as well as on possible ways to target this atypical transporter for future therapeutic strategies.
Institutions: Douglas Mental Health University Institute, McGill University, Centre National de la Recherche Scientifique, Inserm, Université Paris Sciences et Lettres, École Normale Supérieure - PSL, Sorbonne Université, Institut de Biologie Paris-Seine, Laboratoire des Biomolécules, Neurosciences Paris-Seine, Université Paris Cité, Unit of Functional and Adaptive Biology, Physiologie De L'Axe Gonadotrope
Language: English
Subfield: Cellular and Molecular Neuroscience
Field: Neuroscience
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $6,700
Funders: Allen Foundation, Fondation Brain Canada, Agence Nationale de la Recherche, Institut National de la Santé et de la Recherche Médicale, Nutricia Research Foundation, Fondation Fyssen, Centre National de la Recherche Scientifique, Université de Paris, Natural Sciences and Engineering Research Council of Canada, Fonds de Recherche du Québec - Santé
OpenAlex ID: W3137902291